Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity.
Itonaga H, Mookhtiar AK, Greenblatt SM, Liu F, Martinez C, Bilbao D, Rains M, Hamard PJ, Sun J, Umeano AC, Duffort S, Chen C, Man N, Mas G, Tottone L, Totiger T, Bradley T, Taylor J, Schürer S, Nimer SD. Itonaga H, et al. Among authors: taylor j. Nat Commun. 2024 Apr 22;15(1):3415. doi: 10.1038/s41467-024-47689-4. Nat Commun. 2024. PMID: 38649367 Free PMC article.
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14).
Nguyen N, Chaudhry S, Totiger TM, Diaz R, Roberts E, Montoya S, Pardo G, Pardo A, Afaghani J, Affer M, Jahn J, Bradley T, Maura F, Kazandjian D, Bilbao D, Chapman J, Landgren O, Hoffman J, Taylor J. Nguyen N, et al. Among authors: taylor j. NPJ Precis Oncol. 2022 Oct 19;6(1):73. doi: 10.1038/s41698-022-00315-2. NPJ Precis Oncol. 2022. PMID: 36261486 Free PMC article.
Targeted Therapy Development in Acute Myeloid Leukemia.
Totiger TM, Ghoshal A, Zabroski J, Sondhi A, Bucha S, Jahn J, Feng Y, Taylor J. Totiger TM, et al. Among authors: taylor j. Biomedicines. 2023 Feb 20;11(2):641. doi: 10.3390/biomedicines11020641. Biomedicines. 2023. PMID: 36831175 Free PMC article. Review.
Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
Totiger TM, Chaudhry S, Musi E, Afaghani J, Montoya S, Owusu-Ansah F, Lee S, Schwartz G, Klimek V, Taylor J. Totiger TM, et al. Among authors: taylor j. J Cell Mol Med. 2023 Feb;27(4):587-590. doi: 10.1111/jcmm.17667. Epub 2023 Feb 1. J Cell Mol Med. 2023. PMID: 36722323 Free PMC article.
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Ossa JA, Jahn J, Affer M, Totiger TM, Coffey D, Chandhok N, Watts J, Cimmino L, Lu SX, Bolli N, Bolton K, Landau H, Park JH, Ganesh K, McPherson A, Sekeres MA, Lesokhin A, Chung DJ, Zhang Y, Ho C, Roshal M, Tyner J, Nimer S, Papaemmanuil E, Usmani S, Morgan G, Landgren O, Maura F. Diamond B, et al. Among authors: taylor j. Blood. 2023 May 11;141(19):2359-2371. doi: 10.1182/blood.2022018244. Blood. 2023. PMID: 36626250 Free PMC article.
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, Jahn J, Sondhi AK, Gajewski S, Tan YSM, Yung S, Urban A, Wang E, Han C, Mi X, Kim WJ, Sievers Q, Auger P, Bousquet H, Brathaban N, Bravo B, Gessner M, Guiducci C, Iuliano JN, Kane T, Mukerji R, Reddy PJ, Powers J, Sanchez Garcia de Los Rios M, Ye J, Barrientos Risso C, Tsai D, Pardo G, Notti RQ, Pardo A, Affer M, Nawaratne V, Totiger TM, Pena-Velasquez C, Rhodes JM, Zelenetz AD, Alencar A, Roeker LE, Mehta S, Garippa R, Linley A, Soni RK, Skånland SS, Brown RJ, Mato AR, Hansen GM, Abdel-Wahab O, Taylor J. Montoya S, et al. Among authors: taylor j. Science. 2024 Feb 2;383(6682):eadi5798. doi: 10.1126/science.adi5798. Epub 2024 Feb 2. Science. 2024. PMID: 38301010 Free PMC article.
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
Bewersdorf JP, Stahl M, Taylor J, Mi X, Chandhok NS, Watts J, Derkach A, Wysocki M, Lu SX, Bourcier J, Hogg SJ, Rahman J, Chaudhry S, Totiger TM, Abdel-Wahab O, Stein EM. Bewersdorf JP, et al. Among authors: taylor j. Leukemia. 2023 Dec;37(12):2512-2516. doi: 10.1038/s41375-023-02050-4. Epub 2023 Oct 9. Leukemia. 2023. PMID: 37814121 Free PMC article. Clinical Trial. No abstract available.
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O. Wang E, et al. Among authors: taylor j. N Engl J Med. 2022 Feb 24;386(8):735-743. doi: 10.1056/NEJMoa2114110. N Engl J Med. 2022. PMID: 35196427 Free PMC article.
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Zeidan AM, et al. Among authors: taylor j. Leukemia. 2022 Dec;36(12):2939-2946. doi: 10.1038/s41375-022-01724-9. Epub 2022 Oct 20. Leukemia. 2022. PMID: 36266326 No abstract available.
14,967 results
You have reached the last available page of results. Please see the User Guide for more information.